Immunovant Net Debt To E B I T D A from 2010 to 2025
| IMVT Stock | USD 18.37 0.42 2.24% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 2.12 | Current Value 1.66 | Quarterly Volatility 1.30100911 |
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 34.8 M or Other Operating Expenses of 341.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.72. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.
Immunovant | Net Debt To E B I T D A |
Latest Immunovant's Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Immunovant over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Immunovant's Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunovant's overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Immunovant Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 1.02 | |
| Geometric Mean | 0.03 | |
| Coefficient Of Variation | 127.80 | |
| Mean Deviation | 1.14 | |
| Median | 0.0009 | |
| Standard Deviation | 1.30 | |
| Sample Variance | 1.69 | |
| Range | 3.7141 | |
| R-Value | 0.75 | |
| Mean Square Error | 0.79 | |
| R-Squared | 0.56 | |
| Significance | 0.0008 | |
| Slope | 0.21 | |
| Total Sum of Squares | 25.39 |
Immunovant Net Debt To E B I T D A History
About Immunovant Financial Statements
Immunovant shareholders use historical fundamental indicators, such as Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 2.12 | 1.66 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.